Clinical Trials Using Autologous Tumor Infiltrating Lymphocytes LN-145
Clinical trials are research studies that involve people. The clinical trials on this list are studying Autologous Tumor Infiltrating Lymphocytes LN-145. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Study of LN-145 / LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145 / LN-145-S1) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and / or metastatic squamous cell carcinoma of the head and neck
Location: 18 locations
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel) / LN-145 in combination with pembrolizumab or TIL LN-145 / LN-145-S1 as a single therapy.
Location: 8 locations
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma
Location: 11 locations
Modified Immune Cells (LN-145) for the Treatment of Pretreated Metastatic Triple Negative Breast Cancer
This phase II trial studies how well modified immune cells (LN-145) work in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). LN-145 is made up of specialized white blood cells called lymphocytes or “T cells” that are derived from a patient's tumor after a small piece is obtained by surgical removal. This piece of the patient's tumor is sent to a centralized manufacturing facility where T cells that have infiltrated the tumor are isolated and grown to create LN-145, which is infused back into the body. Tumor infiltrating lymphocyte therapy with LN-145 involves expanding and activating tumor-derived T cells in vitro (in tissue culture) and then infusing the cells back into the patient where they may then attack the tumor.
Location: Yale University, New Haven, Connecticut
LN-145 in Treating Patients with Relapsed or Refractory Ovarian Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) works in treating patients with ovarian cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. The T cells may specifically recognize, target, and kill the tumor cells.
Location: M D Anderson Cancer Center, Houston, Texas